Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Latest news

Opdivo drives gain in BMS sales, but business revamp coming

Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
Shire gives up on Momenta-partnered Humira biosimilar

It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate

Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers
NICE backs four treatments for juvenile idiopathic arthritis

NICE backs four treatments for juvenile idiopathic arthritis. Includes BMS' Orencia and AbbVie's Humira. ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept) and Roche's RoActemra
NICE backs biosimilars in rheumatoid arthritis guidance

Orencia (abatacept) and MSD/J&J's Remicade (infliximab).

More from news
Approximately 10 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Deal Watch January 2016

255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
Biosimilars - the same, but different?

Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS’ Brian Daniels to retire

Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editorial Director – Medical Education – Oxford: Negotiable

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Scientific Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Senior Programme Executive: Salary TBC

Senior Medical Writer: Great salary and bebefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Manager – Med Comms – London: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Subscribe to our email news alerts

PMHub

Add my company

StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...